Bharat Immunologicals (India) Valuation

Bharat Immunologicals shows prevailing Real Value of USD35.25 per share. The current price of the firm is USD32.3. At this time the firm appears to be under valued. Macroaxis approximates value of Bharat Immunologicals from analyzing the firm fundamentals such as Profit Margin of (4.18)% and Return On Equity of (11.52)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
Investment Horizon     30 Days    Login   to change

Bharat Immunologicals Total Value Analysis

Bharat Immunologicals Biologicals Corp Ltd is currently anticipated to have takeover price of 862.5 M with market capitalization of 844.17 M, debt of 177.56 M, and cash on hands of 152.27 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bharat Immunologicals fundamentals before making investing decisions based on the enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
862.5 M844.17 M177.56 M152.27 M

Bharat Immunologicals Investor Information

Book value of the company was currently as 8.21. The company recorded loss per share of 1.24. Bharat Immunologicals Biologicals Corp Ltd had not issued any dividends in recent years. Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals solutions in India. For more info on BHARAT IMUNO(BSE please contact the company at 91 57 3223 8758 or go to http://www.bibcol.com.

Bharat Immunologicals Asset Utilization

Bharat Immunologicals Biologicals Corp Ltd shows negative operation of assets of -1.69 percent, earning only USD0.02 for each dollar of assets held by the firm. Unsuccessful assets utilization signifies that the company is being less effective with each dollar of assets it shows. In plain English assets utilization of Bharat Immunologicals Biologicals Corp Ltd shows how unproductive it operates for each dollar spent on its assets.

Bharat Immunologicals Profitability Analysis

The company reported revenue of 1.28 B. Net Loss for the year was (53.46 M) with profit before overhead, payroll, taxes, and interest of 119 M.
 Profitability 
Benchmark  Embed    Values 
Under Valued
April 25, 2017
32.3
Market Value
Downside upside
35.25
Real Value
Target Price Odds
 Above  Below  
52.29
Upside
Upside upside
Bharat Immunologicals is not very volatile asset. Calculation of real value of Bharat Immunologicals is based on 1 month time horizon. Increasing Bharat Immunologicals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Revenue

Bharat Immunologicals Revenue
Based on latest financial disclosure Bharat Immunologicals Biologicals Corp Ltd reported 1.28 B of revenue. This is much higher than that of the sector, and significantly higher than that of Revenue industry, The Revenue for all stocks is over 1000% lower than the firm.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.